At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
4 articles- Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseasesGlobeNewswire Biotech·2026-06-19press release
- Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral PresentationGlobeNewswire Biotech·2026-06-15press release
- Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy winBioSpace·2026-06-12
- <a href="https://www.fiercebiotech.com/biotech/novartis-data-tee-regulatory-talks-about-asset-12b-avidity-takeover" hreflang="en">Novartis' phase 1/2 win tees up regulatory talks about dystrophy drug from $12B Avidity takeover</a>FierceBiotech
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
MIVetsCan: Cannabis Coaching for Veteran Pain Management Trial (Phase 1)
In Brief
A clinical study evaluating Educational Session for Chronic Pain. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The goal of the MIVetsCan Can-Coach Trial is to pilot and modify a trial of four coaching sessions to help Veterans with chronic pain use their own cannabis products more effectively to manage pain and related symptoms.
Study Details
Timeline
Arms & Interventions
Prior to the educational sessions, study participants will be given access to educational materials (e.g., handouts, videos) that provide an overview of information regarding cannabis products, effects, and pain. These materials will be developed with insight from the study team and the Community Advisory Board. Educational content will include known side effects of cannabis (e.g., common effects like dizziness or sedation, rare side effects like hallucinations or vomiting) as well as specific risks associated with administration routes, such as respiratory harm from smoking or unregulated vaporized concentrate products, and the delayed onset of edible products. Sessions will help the participants appropriately select products for use.
Interventions
The initial session will last about 45 to 60 minutes. The subsequent 3 sessions are anticipated to take about 20-30 minutes.